Announcements Trials
Browse Landscape

Phase

Phase 2 58Phase 1 23Phase 3 11Phase 1/2 9Phase NA 2Phase 4 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Melphalan × 1 year × Clear all
NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡